KITE | Jotup

IDEOlogy Health Appoints Sandra Park as General Counsel and Chief Compliance Officer

Retrieved on:

월요일, 11월 6, 2023

FDA, Assistant, Physician, Publication, Ideology, Biopharma LLC, University of North Carolina, Chapel Hill, George Mason University, Pharmacy, University, Genentech, General counsel, Pharmaceutical industry

AUSTIN, Texas, Nov. 6, 2023 /PRNewswire/ -- IDEOlogy Health, a leading medical education company, announced that Sandra Park will join the company as General Counsel and Chief Compliance Officer effective today.

Key Points:

AUSTIN, Texas, Nov. 6, 2023 /PRNewswire/ -- IDEOlogy Health, a leading medical education company, announced that Sandra Park will join the company as General Counsel and Chief Compliance Officer effective today.
Sandra will lead the legal and compliance functions for IDEOlogy Health, providing internal stakeholders with strategic and solutions-oriented advice and legal direction.
"I am thrilled to join IDEOlogy's mission in providing unbiased medical information to their network of physicians," said Sandra Park.
Prior to Kite, Sandra served as Assistant General Counsel at Genentech, Regulatory Counsel at the FDA, and outside counsel for a wide variety of healthcare clients.

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

Retrieved on:

화요일, 10월 31, 2023

Oncology, Health, Stem Cells, Hospitals, Genetics, Pharmaceutical, Biotechnology, Gene, Translational medicine, CAR, Cancer, EPS, GAAP, Patient, Bone marrow, Cell biology, Pharmaceutical industry

Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.

Key Points:

Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.
“Cell-based cancer immunotherapies have reshaped modern cancer care, but we have still only scratched the surface of their potential benefit for patients.
Kite will make an upfront payment to Epic Bio and Epic Bio will be eligible to receive performance-based development, regulatory and sales milestone payments.
Epic Bio is also eligible to receive tiered royalties on any approved products that result from the collaboration.

Next-Generation Commerce Platform Kite Appoints CPTO and CFO

Retrieved on:

목요일, 8월 31, 2023

NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Kite, a next-generation commerce company specializing in scaling high-potential brands, announced today the appointment of Mike Hart, former VP of Product at Fletch and Amazon product management and engineering executive, as CPTO and Markus Leunig, former CFO of Walker Edison and The North Face, as CFO.

Key Points:

NEW YORK, Aug. 31, 2023 /PRNewswire/ -- Kite , a next-generation commerce company specializing in scaling high-potential brands, announced today the appointment of Mike Hart , former VP of Product at Fletch and Amazon product management and engineering executive, as CPTO and Markus Leunig , former CFO of Walker Edison and The North Face, as CFO.
"The foundation of an exceptional company lies in the brilliance of its people," said Rob Solomon, Co-Founder and CEO of Kite.
Mike Hart, CPTO of Kite, has spent his career building platforms and ground-breaking products using machine learning at iconic technology companies and startups.
Prior to Kite, Mike was the VP of Product for data analytics platform Fletch, and led product and engineering teams at companies including Amazon, Netflix, and Microsoft.

Kite Mobility secures $3.5M in capital, to accelerate growth and continue leading the private electric vehicle rideshare market

Retrieved on:

화요일, 8월 29, 2023

Well, Carbon, Good, Housing, Construction, EV, TAF, GHG, AEF, One Good Well (album), LC3, Growth, City, Transport, Renewable energy

TORONTO, Aug. 29, 2023 /CNW/ - Kite Mobility's 3rd seed round will help accelerate rapid growth across Canada.

Key Points:

TORONTO, Aug. 29, 2023 /CNW/ - Kite Mobility's 3rd seed round will help accelerate rapid growth across Canada.
Kite's electric mobility-sharing solution can displace up to 10 parking spots per 1 shared electric vehicle, allowing building developers to save several millions in capital costs per project.
We look forward to accelerating Kite's growth by leveraging our long standing and trusted relationships in the development community."
Kite plans to accelerate projects in lock-step with leading real estate developers, and together, innovate and offer solutions to pressing carbon reduction challenges within buildings and communities.

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan

Retrieved on:

목요일, 6월 22, 2023

Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, Gilead Sciences, Pharma, Partnership, Competition and Markets Authority, Cancer, Axicabtagene ciloleucel, Marketing, CAR, Hospital, Patient, Daiichi Sankyo, Kite Pharma, Pharmaceutical industry

Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.

Key Points:

Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc.
This follows the announcement made by Daiichi Sankyo and Kite Pharma, Inc. in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta®.
With this completion of the Marketing Authorization transfer, the sales and promotion activities of Yescarta® in Japan now will be managed by the Kite Cell Therapy Business Unit of Gilead Sciences K.K.
“We look forward to advancing new treatments in oncology with the potential to positively impact the lives of people with cancer in Japan.”

Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

Retrieved on:

목요일, 6월 15, 2023

Galapagos NV, CET, LIVN, Euronext, JNJ, Investment, Patient, Executive Committee, CFO, Johnson & Johnson, R, NYSE, LivaNova, Management, Galápagos Islands

Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023.

Key Points:

Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023.
Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ: GILD).
“On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad.
“I am very excited to join Galapagos and to work with Paul and the team to realize the company’s full potential,” added Thad Huston.

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Retrieved on:

화요일, 5월 16, 2023

Oncology, Health, Hospitals, Stem Cells, Pharmaceutical, Biotechnology, Cancer, Business, Multimedia, Johns Hopkins University, Patient, Polymerase chain reaction, Science, Foundation Medicine, PCR, Sarah Cannon Research Institute, Management, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.

Key Points:

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
View the full release here: https://www.businesswire.com/news/home/20230516005214/en/
Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire)
Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care.
“Cindy has more than 20 years’ experience in scientific and commercial leadership in oncology and has dedicated her career to improving the care of cancer,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead.
I believe with the continued focus and commitment of the Kite team we will be able to reach many more cancer patients around the world.”

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

Retrieved on:

목요일, 4월 20, 2023

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.

Key Points:

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.
Mr. Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.
Once again, we both look forward to bringing to patients the next generation CAR T,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
Most recently, he continued his effort of advancing the field of engineered cell manufacturing as Chief Operating Officer of Instil Bio, and President and Chief Operating Officer of PACT Pharma.

Next-Generation Commerce Platform Kite Closes on $200 Million of Equity, Announces Rob Solomon as Co-Founder & CEO

Retrieved on:

월요일, 4월 10, 2023

NEW YORK, April 10, 2023 /PRNewswire/ -- Kite, a next-generation commerce company specializing in scaling high-potential brands, announced today that it has closed on a commitment of $200 million in equity from funds managed by Blackstone and founding partner Juxtapose. The company will be led by Rob Solomon, former CEO and Chairman of GoFundMe, who brings over two decades of experience in product and business development, operations management, M&A, and brand launches to his role as Kite Co-Founder and CEO.

Key Points:

Kite is an "every channel" commerce platform designed from the ground up to support digital-first consumer product brands.
"Today, entrepreneurial brands aren't set up to thrive because commerce infrastructures are siloed, fragmented, and inefficient," said Solomon.
As the platform matures and expands, we will refine our ability to make data-driven strategic decisions to intelligently scale our brands."
"Under Rob Solomon's leadership, Kite is building a world class team and commerce platform to reimagine how the best emerging brands scale to reach more customers, design inspired products and deliver sustainable growth."

Security Luminaries Join Black Kite’s Board of Advisors

Retrieved on:

화요일, 3월 28, 2023

Software, Technology, Networks, Security, Insurance, Advisory board, Risk management, CISO, Government, Organization, Risk, BAE Systems, Growth, FAIR, Black kite

Black Kite , the leader in third-party cyber risk intelligence, today announced Alpa Inamdar and JC Dodson have joined the company’s Advisory Board.

Key Points:

Black Kite , the leader in third-party cyber risk intelligence, today announced Alpa Inamdar and JC Dodson have joined the company’s Advisory Board.
“At Black Kite, we have the boldest minds in the industry working together to provide next-level cyber risk intelligence that’s ahead of the competition,” said Paul Paget, CEO of Black Kite.
“When it comes to third-party cyber risk intelligence, Black Kite is a true trailblazer that’s changing how security is discussed and managed,” said Inamdar.
I am thrilled to join the Advisory Board and help the team meet record demand in building safer, more resilient digital supply chains.”
Dodson brings 40 years of government and industry experience in advanced technology development and enterprise-wide security risk management to Black Kite’s Advisor Board.